Bank of America Lifts REGN Target to 1,030, Signaling Upside
Nov 2, 2026, 8:48 AM EST2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
A high-profile target increase (to 1,030) with Buy rating supports upside potential and may trigger short-term buying pressure if REGN reacts to the re-rating, as seen in similar upgrades historically.
AI summary
What happened, with direct paths to the underlying reporting
Bank of America Securities boosted Regeneron's price target to $1,030 while keeping a Buy rating, after REGN closed at $927.89 on Friday. The upgrade implies roughly 11% upside and reflects optimism for REGN's growth trajectory, potentially attracting near-term buying interest as investors reassess REGN's valuation against peers.
BofA raises REGN target to $1,030; Buy rating unchanged.
REGN closed at $927.89 Friday; ~11% upside implied.
REGN stands out as target uplift signals re-rating potential.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Regeneron is set to report Q3 results with consensus EPS of $16.19 on $4.56B revenue. The BARDA extension for Inmazeb strengthens US preparedness and could support near-term deman…
Regeneron extended its supply contract with a U.S. health authority to deliver additional doses of its Ebola treatment REGN-EB3 amid a growing outbreak in Africa. The move signals…
Regeneron reported 84-week results from the OPTIMA Phase 3 trial of Pasatru in fibrodysplasia ossificans progressiva, showing sustained suppression of new heterotopic bone formati…
Sanofi and Regeneron expanded their alliance to add REGN20423 and other long-acting antibodies, with a $1 billion upfront and up to $7 billion in milestones. The four Regeneron in…